Brokers Issue Forecasts for TARA FY2026 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for Protara Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings of ($1.45) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.18.

Several other equities research analysts also recently weighed in on the company. Jones Trading raised Protara Therapeutics to a "strong-buy" rating and set a $21.00 target price for the company in a research report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Monday, April 28th. Lifesci Capital started coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 target price on the stock. Finally, Scotiabank initiated coverage on shares of Protara Therapeutics in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 target price for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $20.50.

Protara Therapeutics Trading Down 3.7%

NASDAQ:TARA traded down $0.12 during mid-day trading on Tuesday, hitting $3.14. The company had a trading volume of 165,447 shares, compared to its average volume of 774,791. The business has a fifty day simple moving average of $3.49 and a 200-day simple moving average of $4.22. The firm has a market capitalization of $121.15 million, a price-to-earnings ratio of -1.11 and a beta of 1.34. Protara Therapeutics has a 1 year low of $1.60 and a 1 year high of $10.48.

Hedge Funds Weigh In On Protara Therapeutics

Several large investors have recently modified their holdings of the stock. Walleye Capital LLC raised its stake in Protara Therapeutics by 3.9% during the first quarter. Walleye Capital LLC now owns 229,454 shares of the company's stock valued at $977,000 after buying an additional 8,640 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Protara Therapeutics by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after acquiring an additional 9,553 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Protara Therapeutics in the 1st quarter valued at approximately $64,000. Commonwealth Equity Services LLC raised its position in shares of Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after acquiring an additional 17,572 shares in the last quarter. Finally, HBK Investments L P bought a new position in Protara Therapeutics during the fourth quarter worth $106,000. Institutional investors own 38.13% of the company's stock.

Insider Buying and Selling at Protara Therapeutics

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the firm's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the transaction, the insider now directly owns 98,861 shares of the company's stock, valued at $447,840.33. This trade represents a 17.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.40% of the stock is owned by insiders.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.